Related Experiment Video
Updated: Sep 7, 2025

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
Synergistic interactions of repurposed drugs that inhibit Nsp1, a major virulence factor for COVID-19
Hung-Teh Kao1, Andrew Orry2, Michael G Palfreyman3
1Sypherion LLC, Providence, RI, 02903, USA. htkao@SypherionBio.com.
Abstract:
Nsp1 is one of the first proteins expressed from the SARS-CoV-2 genome and is a major virulence factor for COVID-19. A rapid multiplexed assay for detecting the action of Nsp1 was developed in cultured lung cells. The assay is based on the acute cytopathic effects induced by Nsp1. Virtual screening was used to stratify compounds that interact with two functional Nsp1 sites: the RNA-binding groove and C-terminal helix-loop-helix region. Experimental screening focused on compounds that could be readily repurposed to treat COVID-19. Multiple synergistic combinations of compounds that significantly inhibited Nsp1 action were identified. Among the most promising combinations are Ponatinib, Rilpivirine, and Montelukast, which together, reversed the toxic effects of Nsp1 to the same extent as null mutations in the Nsp1 gene.
Insights
Scientists developed a new assay to detect the action of SARS-CoV-2
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- The SARS-CoV-2 Nsp1 protein is a key virulence factor in COVID-19 pathogenesis.
- Nsp1 interferes with host cell functions, contributing to disease severity.
Purpose of the Study:
- To develop a novel assay for detecting Nsp1 activity in cultured lung cells.
- To identify existing drugs that can inhibit Nsp1's detrimental effects.
- To discover synergistic drug combinations for COVID-19 treatment.
Main Methods:
- Development of a rapid multiplexed assay based on Nsp1-induced cytopathic effects.
- Virtual screening of compounds targeting Nsp1's RNA-binding groove and C-terminal region.
- Experimental screening of drug-repurposing candidates and their combinations.
Main Results:
- Identification of multiple synergistic compound combinations that inhibit Nsp1 activity.
- Ponatinib, Rilpivirine, and Montelukast demonstrated significant inhibition of Nsp1.
- This combination reversed Nsp1's toxic effects comparably to genetic Nsp1 inactivation.
Conclusions:
- A novel assay effectively measures Nsp1 activity and identifies inhibitors.
- Drug repurposing strategies can yield effective combinations against Nsp1.
- Ponatinib, Rilpivirine, and Montelukast represent a promising therapeutic combination for COVID-19.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Antimicrobial Effectiveness
Gene Regulation in Microbial Communities: Quorum Sensing

